Immunocore Holdings plc ADR 2024年度报告

(Mark One) xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from________to________Commission File Number001-39992Immunocore Holdings plc (Exact name of registrant as specified in its charter) Not Applicable (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation) 92 Park DriveMilton ParkAbingdon, Oxfordshire,United KingdomOX14 4RY(Address of principal executive offices)(Zip code) Tel: +441235438600(Telephone Number) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of each classAmerican Depositary Shares, each representingone ordinary share, nominal value £0.002 pershare Trading Symbol(s)IMCR Name of each exchange on which registeredThe Nasdaq Stock Market LLC Ordinary share, nominal value £0.002 per share* The Nasdaq Stock Market LLC* *Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.xYesoNo Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of1934.oYesxNo Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.xYesoNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).xYesoNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerxAccelerated fileroNon- accelerated fileroSmaller reportingcompanyoEmerging growthcompanyo If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report.x If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.o Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).oYesxNo The aggregate market value of the voting and non-voting ordinary shares held by non-affiliates of the registrant, based upon $33.89,the closing price of the registrant’s American Depositary Shares on the Nasdaq Global Market on June28, 2024 (the last business dayof the registrant’s most recently completed second fiscal quarter) was approximately$1.6billion. As ofJanuary31, 2025, the registrant had50,068,126ordinary shares (including ordinary shares in the form of American DepositaryShares) outstanding, par value £0.002, shares consisting of (i)49,333,729voting ordinary shares and734,397non-voting ordinaryshares. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A inconnection with the registrant’s2025Annual General Meeting of Shareholders are incorporated by reference into Part III of thisAnnual Report on Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120days following the end of the registrant’s fiscal year endedDecember31, 2024. TABLE OF CONTENTS SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains for